CLAIMS

What is claimed is:

1. A method of treating rejection of a corneal transplant in a mammal, said method comprising administering to an eye of said mammal having said transplant a composition comprising an antibody to tumor necrosis factor alpha.

2. The method of claim 1, wherein said composition is administered topically to said eye.

3. The method of claim 1, wherein said mammal is a human.

4. The method of claim 1, wherein said antibody is a polyclonal antibody.

5. The method of claim 1, wherein said antibody is a monoclonal antibody.

6. The method of claim 1, wherein said antibody is a humanized antibody.

7. The method of claim 1, wherein said antibody is a biologically active fragment of an antibody to tumor necrosis factor alpha.

8. The method of claim 1, wherein said antibody is a heavy chain antibody.

9. The heavy chain antibody of claim 8, wherein said heavy chain antibody is selected from the group consisting of a camelid antibody, a heavy chain disease antibody, and a variable heavy chain immunoglobulin.

10. The method of claim 1, wherein said composition is suspended in a pharmaceutically acceptable carrier.

11. A method of treating rejection of a corneal transplant in a mammal, said method comprising administering to an eye of said mammal having said transplant a composition comprising a combination of an antibody to interferon gamma and an antibody to tumor necrosis factor alpha.

12. The method of claim 11, wherein said composition is administered topically to said eye.

13. The method of claim 11, wherein said mammal is a human.

14. The method of claim 11, wherein said antibody is a polyclonal antibody.

15. The method of claim 11, wherein said antibody is a monoclonal

antibody.

16. The method of claim 11, wherein said antibody is a humanized antibody.

17. The method of claim 11, wherein said antibody is a combination of a biologically active fragment of an antibody to tumor necrosis factor alpha and a biologically active fragment of an antibody to interferon gamma.

18. The method of claim 11, wherein said antibody is a heavy chain antibody.

19. The heavy chain antibody of claim 18, wherein said heavy chain antibody is selected from the group consisting of a camelid antibody, a heavy chain disease antibody, and a variable heavy chain immunoglobulin.

20. The method of claim 11, wherein said composition is suspended in a pharmaceutically acceptable carrier.